Presented at ASH 2025: EPCORE CLL-1 trial on epcoritamab monotherapy for Richter transformation
Failed to add items
Add to basket failed.
Add to wishlist failed.
Remove from wishlist failed.
Adding to library failed
Follow podcast failed
Unfollow podcast failed
Presented at ASH 2025: EPCORE CLL-1 trial on epcoritamab monotherapy for Richter transformation
-
Narrated by:
-
By:
Arnon Kater joins Daniela Marin of The Lancet Haematology to discuss the phase 1b/2 EPCORE CLL-1 trial of epcoritamab monotherapy for Richter transformation, which is being presented at ASH 2025.
Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00327-8/fulltext
Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv
The Lancet Haematology in conversation with... is part of the Lancet Group podcast offering.
Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin
Podcast editing: Matteo Simonetti
Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering.
Find the best science for better lives at www.thelancet.com Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv